This video series addresses the role of PCSK9 inhibiting approaches in treating hypercholesterolemia and in preventing CV events in patients at high and very high CV risk. Member registration (free) is needed to enroll in this course.
Prof. Steg presents data of the ODYSSEY Outcomes trial in specific subgroups of ACS patients that benefit most from alirocumab therapy, and discusses the effect of this PCSK9 inhibitor by baseline Lp(a) levels.
In the FOURIER trial, evolocumab reduced LDL-c by ~60% in patients with established CVD. Prof. Sabatine highlights subgroups of high-risk patients who benefit most from treatment with this PCSK9 inhibitor.
Prof. Kastelein discusses new strategies to target PCSK9, including twice-a-year injections of inclisiran and a newly developed oral PCSK9 inhibitor.